Giulio Mattedi
Research Scientist (Advanced Computational Chemist) at BenevolentAI - New York, NY, US
Giulio Mattedi's Colleagues at BenevolentAI
Michelle Mahar
Executive Assistant to the President and Vice President of Proximagen and CEO of Pairnomix
Giulio Mattedi's Contact Details
+44 20 3781 9360
London, England, United Kingdom
BenevolentAI
Giulio Mattedi's Company Details
BenevolentAI is a pioneer and leader in applying advanced explainable AI to drug discovery and development. In a world where the drug development failure rate still exceeds 90% and thousands of complex diseases lack effective treatment, our technology can increase the probability of success and reduce timelines. Our proprietary Benevolent Platform™ is one of the industry’s most established and validated AI drug discovery technologies. In 2020, it took our scientists just 48 hours to identify baricitinib as a potential treatment for COVID-19. This became the first AI-identified drug indication to receive full FDA approval. Our expertise in target identification and in-silico drug design is validated by extended collaborations with partner pharmaceutical companies such as AstraZeneca and Merck. Additionally, our own pipeline of highly differentiated first-in-class and best-in-class assets, provides further avenues for value creation. We unite science and technology to serve patients with complex diseases – because it matters. BenevolentAI is headquartered in London, with our own state-of-the-art biology and chemistry laboratories in Cambridge, UK.